Data / Form D filings / TESARO, Inc.
TESARO, Inc.: Form D filings
TESARO, Inc., a pharmaceuticals company in Waltham, MA, filed 4 Form D notices with the SEC between 2010 and 2016. The latest, on April 18, 2016, reports $50 million sold of a $50 million offering to 1 investor.
Find out what TESARO, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1000 WINTER STREET, SUITE 3300, Waltham, MA, 02451
- Phone
- (339) 970-0900
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- $1 - $1,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1491576
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 18, 2016 | New notice | $49,999,960 | $49,999,960 | $0 | 1 | Apr 5, 2016 | sec.gov |
| Mar 10, 2016 | New notice | $154,999,915 | $154,999,915 | $0 | 7 | Feb 24, 2016 | sec.gov |
| Jun 21, 2011 | New notice | $101,000,000 | $40,000,000 | $61,000,000 | 17 | Jun 6, 2011 | sec.gov |
| May 20, 2010 | New notice | $20,000,000 | $10,000,000 | $10,000,000 | 5 | May 10, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Grant C. Bogle | Executive Officer | |
| Timothy R. Pearson | Executive Officer | |
| Leon O. Moulder, Jr. | Executive Officer, Director | |
| Mary Lynne O. Hedley | Executive Officer, Director | |
| Jeffrey H. Hanke | Executive Officer | |
| Kavita C. Patel | Director | |
| Lawrence M. Alleva | Director | |
| Earl M. Collier, Jr. | Director | |
| Martin H. Huber | Executive Officer | |
| Joseph L. Farmer | Executive Officer | |
| James O. Armitage | Director | |
| Garry A. Nicholson | Director | |
| David M. Mott | Director | |
| Beth L. Seidenberg | Director | |
| Arnold L. Oronsky | Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- BridgeHealth Pharmaceuticals, Inc. $3.5 million · Nov 5, 2026
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Apr 18, 2016 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what TESARO, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.